Multicenter prospective observational study for adjuvant chemotherapy using the eighth edition lung cancer TNM classification and clinical staging system (ILO1804) - Multicenter prospective observational study for adjuvant chemotherapy using the eighth edition lung cancer TNM classification and clinical staging system (ILO1804)

International Lung-clinical-Research Organization0 个研究点目标入组 962 人开始时间: 2021年4月16日最近更新: 2023年11月20日

适应症

试验速览

暂无简介。

•1) The patients had tumors where genetic testing cannot be performed for some reason (insufficient sample volume, etc. 2) Active double cancer, excluding the following curable cases even if the disease-free period is within 5 years; carcinoma in situ or mucosal cancer, prostate cancer (stage I), gastric cancer (stage 0-I), colorectal cancer (stage 0-I), esophageal cancer (stage 0), breast cancer (stage 0), thyroid cancer (papillary or follicular cancer, stage I-III), renal cancer (clear cell carcinoma or chromophobe cell cancer, stage I). 3) The patients were dead within 30 days after surgery. 4) The patients were pregnant or breastfeeding, and the patients may be pregnant, or will be pregnant, or willing to get pregnant. 5) The patients were difficult to participate in the study because of psychosis and/or mental illness. 6) The patients had grade 3 or higher adverse events 7) The attending physician judged that it was inappropriate for the patient to participate in the study. 8) The patients refused to participate in the study.

发起方

International Lung-clinical-Research Organization